238. ビタミンＤ抵抗性くる病／骨軟化症 Disease details / Clinical trials / Drug dev / DR info

68GA-DOTA-tate PET/MR and PET/CT imaging
   Wuhan Union Hospital, China
      2019   -   NCT04045834   China
68GA-dotatate PET/CT
   Mayo Clinic
      2019   Phase 1/Phase 2   NCT03736564   United States
Alfacalcidol
   Haukeland University Hospital
      2009   -   NCT01057186   Norway
BGJ398
   National Institute of Dental and Craniofacial Research (NIDCR)
      2019   Phase 2   NCT03510455   United States
Burosumab
   Kyowa Kirin Co., Ltd.
      2018   -   NCT03775187   -
      2018   Phase 3   JPRN-jRCT2080225188   Asia except Japan;Japan
      2017   Phase 3   JPRN-jRCT2080223558   Japan
      2015   Phase 2   JPRN-jRCT2080223136   Asia except Japan;Japan
   Kyowa Kirin, Inc.
      2015   Phase 2   NCT02304367   United States
   Redwood Dermatology Sciences
      2018   Phase 3   NCT03581591   United States
Cinacalcet
   Children's Mercy Hospital Kansas City
      2009   -   NCT00844740   United States
      2005   Phase 1   NCT00195936   United States
Crysvita (burosumab-twza) treatment
   University of Alabama at Birmingham
      2020   Phase 4   NCT04320316   United States
Growth hormone
   Shandong Provincial Hospital Affiliated to Shandong First Medical University
      2023   Phase 0   ChiCTR2300068368   China
Iron
   Indiana University
      2014   -   NCT02233322   United States
KRN23
   Kyowa Hakko Kirin Co., Ltd
      2014   Phase 1   NCT02181764   Japan;Korea, Republic of
   Kyowa Kirin Co., Ltd.
      2022   Phase 4   NCT05357573   China
      2021   Phase 4   NCT04842032   China
      2021   Phase 4   NCT04842019   China
      2018   Phase 3   NCT04308096   Japan;Korea, Republic of
      2018   Phase 3   JPRN-jRCT2080225188   Asia except Japan;Japan
      2017   Phase 3   NCT03233126   Japan
      2017   Phase 3   JPRN-jRCT2080223558   Japan
      2016   Phase 2   NCT02722798   Japan;Korea, Republic of
      2015   Phase 2   JPRN-jRCT2080223136   Asia except Japan;Japan
Norditropine simplex
   Bicetre Hospital
      2006   Phase 1/Phase 2   NCT02720770   -
Osteoblast biology study
   Hospices Civils de Lyon
      2020   -   NCT04159675   France
Osteomalacia
   ASOU Yoshinori
      2022   Phase 2   JPRN-jRCTs031210704   -
   National Institute of Dental and Craniofacial Research (NIDCR)
      2012   Phase 1   NCT01748812   United States
   The Second Xiangya Hospital, Central South University
      2006   -   ChiCTR-OOC-16010095   China
Paricalcitol
   Yale University
      2007   Phase 3   NCT00417612   United States
Phosphate
   Haukeland University Hospital
      2009   -   NCT01057186   Norway
   The Second Xiangya Hospital, Central South University
      2006   -   ChiCTR-OOC-16010095   China
   University of Aarhus
      2015   -   NCT03348644   Denmark
Phosphorus
   The Second Xiangya Hospital, Central South University
      2006   -   ChiCTR-OOC-16010095   China
   Zeria Pharmaceutical Co., Ltd.
      2010   Phase 3   JPRN-jRCT2080221295   -
Sevelamer
   Haukeland University Hospital
      2009   -   NCT01057186   Norway
Somatropin
   University of Rostock
      2004   Phase 1   NCT00473187   Germany
TM5614
   ASOU Yoshinori
      2022   Phase 2   JPRN-jRCTs031210704   -
Z-521
   Zeria Pharmaceutical
      2010   Phase 3   NCT01237288   Japan
   Zeria Pharmaceutical Co., Ltd.
      2010   Phase 3   JPRN-jRCT2080221295   -